{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:13:31Z","timestamp":1792476811836,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":210,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.nsa.2025.105525","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T16:01:48Z","timestamp":1753977708000},"page":"105525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena D.","family":"Aicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Hawrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-584X","authenticated-orcid":false,"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2025.105525_bib1","article-title":"Treatment recommendations for psychedelic-assisted therapy","volume":"175","author":"Aicher","year":"2024","journal-title":"Swiss Arch Neurol Psychiatr Psychother"},{"key":"10.1016\/j.nsa.2025.105525_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12909-025-06871-y","article-title":"Further education in psychedelic-assisted therapy: experiences from Switzerland","volume":"25","author":"Aicher","year":"2025","journal-title":"BMC Med. Educ."},{"key":"10.1016\/j.nsa.2025.105525_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00278-024-00711-y","article-title":"Psychedelika-assistierte Psychotherapie: Erfahrungen mit der beschr\u00e4nkten medizinischen Anwendung von LSD, MDMA und Psilocybin in der Schweiz","volume":"69","author":"Aicher","year":"2024","journal-title":"Psychotherapies"},{"key":"10.1016\/j.nsa.2025.105525_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5582\/irdr.2016.01054","article-title":"An overview of compassionate use programs in the european union member states","volume":"5","author":"Balasubramanian","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.nsa.2025.105525_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.nsa.2025.105525_bib6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cpt.3618","article-title":"Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial","volume":"117","author":"Becker","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.nsa.2025.105525_bib7","first-page":"38","article-title":"Medizinische Behandlung mit Psychedelika","volume":"104","author":"Br\u00fchl","year":"2023","journal-title":"Schweiz \u00c4rzteztg"},{"key":"10.1016\/j.nsa.2025.105525_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/02698811241278873","article-title":"Naturalistic psychedelic therapy: the role of relaxation and subjective drug effects in antidepressant response","volume":"38","author":"Calder","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib9","series-title":"EMA multi-stakeholder Workshop on Psychedelics: Workshop Report EMA\/222339\/2023","year":"2024"},{"key":"10.1016\/j.nsa.2025.105525_bib10","first-page":"3","article-title":"Psycholytic therapy with MDMA and LSD in Switzerland","volume":"5","author":"Gasser","year":"1994","journal-title":"MAPS Newsletter"},{"key":"10.1016\/j.nsa.2025.105525_bib11","first-page":"59","article-title":"Die psycholytische Therapie in der Schweiz von 1988-1993","volume":"147","author":"Gasser","year":"1996","journal-title":"Schweiz. Arch. Neurol. Psychiatr."},{"key":"10.1016\/j.nsa.2025.105525_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.nsa.2025.105525_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-Assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib14","series-title":"Reimbursement Pathways for Psychedelic Therapies in Europe","author":"Gisby","year":"2025"},{"key":"10.1016\/j.nsa.2025.105525_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.nsa.2025.105525_bib16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","volume":"239","author":"Holze","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2025.105525_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nsa.2025.105525_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2024.99","article-title":"LSD-Assisted therapy in people with anxiety: an open-label prospective 12-month follow-up","volume":"225","author":"Holze","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.nsa.2025.105525_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.954388","article-title":"Study protocol for \"MDMA-assisted therapy as a treatment for major depressive disorder: a proof of principle study.\"","volume":"13","author":"Kvam","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.nsa.2025.105525_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2021_270","article-title":"Dosing psychedelics and MDMA","volume":"56","author":"Liechti","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.nsa.2025.105525_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2025.0044","article-title":"Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial","volume":"82","author":"Mueller","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.nsa.2025.105525_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116381","article-title":"Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report","volume":"345","author":"Muller","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.nsa.2025.105525_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib24","article-title":"Psychedelic-augmented psychotherapy for overcomming traumatic dissociation: a review of neuroscientific and phenomenological evidence","volume":"8","author":"Rougemont-B\u00fccking","year":"2024","journal-title":"Eur J Tauma Dissoc"},{"key":"10.1016\/j.nsa.2025.105525_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nsa.2025.105525_bib26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269881120959604","article-title":"Acute subjective effects in LSD- and MDMA-Assisted psychotherapy","volume":"35","author":"Schmid","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104060","article-title":"Safety pharmacology of acute psilocybin administration in healthy participants","volume":"3","author":"Straumann","year":"2024","journal-title":"Neurosci Appl"},{"key":"10.1016\/j.nsa.2025.105525_bib28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/0269881121998322","article-title":"Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies","volume":"35","author":"Studerus","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2025.105525_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41398-024-03074-9","article-title":"Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants","volume":"14","author":"Vizeli","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nsa.2025.105525_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.npp.1395197","article-title":"Psychological and cardiovascular effects and short-term sequelae of MDMA (\"ecstasy\") in MDMA-Naive healthy volunteers","volume":"19","author":"Vollenweider","year":"1998","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408525001176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408525001176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:02:49Z","timestamp":1772920969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772408525001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":31,"alternative-id":["S2772408525001176"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2025.105525","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2025.105525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"105525"}}